Whalesbook
Earnings Collapse and Margin Erosion
Cipla's fourth quarter ending March 2026 saw a steep fall in profitability driven by falling revenue and shrinking margins. Revenue decreased 2.8% year-on-year to ₹6,541 crore, reflecting challenges in key markets. More significantly, EBITDA margins dropped sharply from 22.8% to 14.6% in Q4 FY26. This margin squeeze, alongside a 37.9% fall in EBITDA to ₹955 crore, significantly cut into profits before taxes. Cipla reported a net profit of ₹555 crore, a 54% drop and below the analyst consensus estimate of ₹716 crore. Revenue also missed expectations, coming in at ₹6,541 crore versus a consensus of ₹6,701 crore. The drastic decline in EBITDA margins signals a core issue in converting sales to profit. The stock, trading around ₹1,300-₹1,305, has a P/E ratio of about 23x, trading at a discount to the Indian pharmaceutical sector average of 34-35x.
US Market Pressures and Rising Costs
Performance in the United States market significantly impacted Cipla's Q4 FY26 revenue. The loss of exclusivity for products like gRevlimid and lower sales of Lanreotide due to supply chain problems created notable revenue gaps. Ongoing pricing pressures and inventory adjustments in the US generics market also played a role. Cipla also faced rising operational expenses. Increased spending on marketing for new products and higher freight costs directly affected profitability, worsening margin pressure and contributing to the drop in EBITDA.
Valuation Discount and Peer Comparison
Cipla's P/E ratio of about 23x represents a discount of roughly 35% compared to the Nifty Pharma index's average P/E of 33.86x. While peers such as Dr. Reddy's Laboratories (18.5x-19x) and Zydus Lifesciences (around 21x) trade at similar valuations, larger companies like Sun Pharma (40x) and Divi's Laboratories (around 70x) command higher multiples. This discount indicates the market is factoring in Cipla's current operational challenges and potential growth hurdles, diverging from the broader positive earnings trend in the pharmaceutical sector.
Analyst Views and Ratings
Analysts hold a mixed to neutral view on Cipla, with the consensus rating leaning towards 'Hold'. Jefferies downgraded the stock to 'Sell', and Bank of America Securities reiterated a 'Sell' rating, citing execution risks. In contrast, ICICI Securities upgraded Cipla to 'Buy' with a target price of ₹1,550, expecting gains from new generics. The average 12-month price target from analysts is around ₹1,430-₹1,435, suggesting limited upside potential and continued caution.
Regulatory Concerns and Market Challenges
Despite the announced ₹13 per share dividend, underlying risks are increasing. Cipla's reliance on the US market, facing patent expiries and strong pricing pressure, poses a challenge to revenue growth. Recent US Food and Drug Administration (USFDA) observations at one of Cipla's facilities noted deficiencies in contamination control, aseptic processing, and laboratory practices. These issues signal potential regulatory obstacles and future compliance costs. Combined with ongoing margin compression and a history of missing earnings estimates in previous quarters, the company faces operational challenges. The stock's consistent underperformance against the Sensex over the past year highlights these weaknesses. Management's ability to navigate these market and regulatory complexities is now under review.
Future Outlook
Looking forward, analysts expect Cipla's revenue to grow moderately. Consensus estimates for 2027 project around ₹309.3 billion, an 11% increase year-on-year. However, earnings per share (EPS) are forecast to be relatively flat at approximately ₹57.17 compared to the last 12 months. Before the latest Q4 results, analysts had predicted higher revenues and EPS, suggesting current performance has led to adjusted expectations. Cipla's success in launching new complex generics in the US and managing regulatory requirements will be key to its future earnings and margin improvement.